JPS6151584B2 - - Google Patents
Info
- Publication number
- JPS6151584B2 JPS6151584B2 JP53061745A JP6174578A JPS6151584B2 JP S6151584 B2 JPS6151584 B2 JP S6151584B2 JP 53061745 A JP53061745 A JP 53061745A JP 6174578 A JP6174578 A JP 6174578A JP S6151584 B2 JPS6151584 B2 JP S6151584B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- carbon atoms
- compound
- compounds
- side chains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 12
- 206010020601 Hyperchlorhydria Diseases 0.000 claims description 9
- 238000005984 hydrogenation reaction Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical group C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- FPTFFTMXBKQFKC-JZKKULJYSA-N Tetranor-PGE1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCC(O)=O FPTFFTMXBKQFKC-JZKKULJYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 230000027119 gastric acid secretion Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001940 cyclopentanes Chemical class 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 230000029860 luteolysis Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- NQTSTBMCCAVWOS-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-phenoxypropan-2-one Chemical compound COP(=O)(OC)CC(=O)COC1=CC=CC=C1 NQTSTBMCCAVWOS-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- OPDQOKREXYCJHD-YUMYIRISSA-N [(1r,4ar,5r,8ar)-4a-formyl-5-[2-(furan-3-yl)ethyl]-1-methyl-6-methylidene-3,4,5,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl acetate Chemical compound C([C@H]1[C@]2(C=O)CCC[C@@]([C@H]2CCC1=C)(C)COC(=O)C)CC=1C=COC=1 OPDQOKREXYCJHD-YUMYIRISSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- -1 al Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IVFPNVDGWGXPMZ-YUMYIRISSA-N potamogetonol Chemical compound C([C@H]1[C@]2(CO)CCC[C@@]([C@H]2CCC1=C)(C)COC(=O)C)CC=1C=COC=1 IVFPNVDGWGXPMZ-YUMYIRISSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯è¬çåŠçæ§è³ªãæããæ°èŠã·ã¯ããã³
ã¿ã³èªå°äœããã®è£œæ³ãããã³ããããå«æããŠ
ããè¬å€çµæç©ã«é¢ããã
ã¿ã³èªå°äœããã®è£œæ³ãããã³ããããå«æããŠ
ããè¬å€çµæç©ã«é¢ããã
è±åœç¹èš±ç¬¬1468830å·æ现æžããªãã³ã«å¯Ÿå¿ã
ãå€åœåºé¡æ现æžäŸãã°ãªã©ã³ãç¹èš±åºé¡ç¬¬
7500868å·ããã³ç±³åœç¹èš±ç¬¬4088695å·æ现æžã«ã
ããŠãäžèšã®äžè¬åŒãæããæ°èŠãªã·ã¯ããã³
ã¿ã³èªå°äœãèšèŒãããŠããã
ãå€åœåºé¡æ现æžäŸãã°ãªã©ã³ãç¹èš±åºé¡ç¬¬
7500868å·ããã³ç±³åœç¹èš±ç¬¬4088695å·æ现æžã«ã
ããŠãäžèšã®äžè¬åŒãæããæ°èŠãªã·ã¯ããã³
ã¿ã³èªå°äœãèšèŒãããŠããã
äžèšã®åŒäžR1ã¯æ°ŽçŽ ååãããã¯ã«ã«ãã³é
ž
ã®ã¢ã·ã«åºãè¡šããããã㊠(i) R2ã¯äžè¬åŒ âCR3R4R5 ïŒåŒäžR3ããã³R4ã¯åãããŸãã¯çžç°ãªã€ãŠ
ããŠãã®ãã®æ°ŽçŽ ååãããã¯çŽéãããã¯æå
ãç¶ã®ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åºã
è¡šãããR5ã¯æ°ŽçŽ ååãããã¯çŽéãããã¯æ
åãç¶ã®ïŒã10åã®ççŽ ååãæããã¢ã«ãã«
åºãçŽéãããã¯æåãç¶ã®ïŒã10åã®ççŽ åå
ãæããã¢ã«ã³ãã·åºãïŒãïŒåã®ççŽ ååãæ
ããã·ã¯ãã¢ã«ãã«åºãã¢ããã³ãã«åºãããã
ã¯çŽéãããã¯æåãç¶ã®ïŒãïŒåã®ççŽ ååã
æããã¢ã«ã³ãã·åºã«ãã€ãŠãïŒãïŒåã®ççŽ å
åãæããã·ã¯ãã¢ã«ãã«åºã«ãã€ãŠãããã¯ã¢
ããã³ãã«åºã«ãã€ãŠçœ®æãããŠããçŽéããã
ã¯æåãç¶ã®ïŒãïŒåã®ççŽ ååãæããã¢ã«ã
ã«åºãè¡šãããããããã¯åºââCR3R4R5ãå ±å
ããŠïŒãïŒåã®ççŽ ååãæããã·ã¯ãã¢ã«ãã«
åºãããã¯ã¢ããã³ãã«åºã圢æããïŒãæãã
åºãè¡šãããã¯ãã©ã³ã¹âããã¬ã³ãããã¯ãš
ãã¬ã³åºãè¡šãããã¯ã«ã«ããã«åºãããã¯äž
è¬åŒ ïŒåŒäžR6ã¯æ°ŽçŽ ååãããã¯çŽéãããã¯æ
åãç¶ã®ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åº
ãè¡šãããR7ã¯æ°ŽçŽ ååãããã¯ã«ã«ãã³é žã¢
ã·ã«åºãè¡šããïŒãæããåºã§ãããããããã¯
ãããªããã° (ii) R2ã¯äžè¬åŒ âââR8 ïŒåŒäžïŒ¡ã¯çŽéãããã¯æåãç¶ã®ïŒã12åã®
ççŽ ååãæããã¢ã«ãã¬ã³éãè¡šãããã¯çŽ
æ¥ã®çµåãè¡šããããããã¯é žçŽ ãããã¯ç¡«é»å
åãè¡šããããããŠR8ã¯äŸãã°ãããã²ã³å
åãçŽéãããã¯æåãç¶ã®ïŒãïŒåã®ççŽ åå
ãæããã¢ã«ãã«ããã³ã¢ã«ã³ãã·åºãããã³ã
ãªããã¡ãã«åºäŸãã°ããªãã«ãªã«ã¡ãã«åºãã
æã矀ããéžæããã眮æåºã®ïŒåãããã¯ãã
以äžã«ãã眮æããããã¢ãªãŒã«ãããã¯è€çŽ ç°
åºãè¡šããïŒãæããåºãè¡šãããåŒã«ããã
ã¯ãšãã¬ã³ãããã¯ãã©ã³ã¹âããã¬ã³åºãè¡š
ãããåŒã«ãããã¯ã«ã«ããã«åºãããã¯åŒ
ïŒåŒäžR6ããã³R7ã¯åèšã®æå³ãæããïŒã
æããåºãè¡šãããããããã¯ãããªããã° (iii) R2ã¯åèšã®åºR8ãè¡šããããããŠåŒã«ã
ããããã³ïŒ¹ã¯åæã«ãšãã¬ã³ããã³ã«ã«ãã
ã«ããã©ã³ã¹âããã¬ã³ããã³ã«ã«ããã«ããã
ãã¯ãšãã¬ã³ããã³âCHïŒOR7ïŒâåºïŒR7ã¯åèš
ã®ãšããã§ããïŒãããããè¡šããã
ã®ã¢ã·ã«åºãè¡šããããã㊠(i) R2ã¯äžè¬åŒ âCR3R4R5 ïŒåŒäžR3ããã³R4ã¯åãããŸãã¯çžç°ãªã€ãŠ
ããŠãã®ãã®æ°ŽçŽ ååãããã¯çŽéãããã¯æå
ãç¶ã®ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åºã
è¡šãããR5ã¯æ°ŽçŽ ååãããã¯çŽéãããã¯æ
åãç¶ã®ïŒã10åã®ççŽ ååãæããã¢ã«ãã«
åºãçŽéãããã¯æåãç¶ã®ïŒã10åã®ççŽ åå
ãæããã¢ã«ã³ãã·åºãïŒãïŒåã®ççŽ ååãæ
ããã·ã¯ãã¢ã«ãã«åºãã¢ããã³ãã«åºãããã
ã¯çŽéãããã¯æåãç¶ã®ïŒãïŒåã®ççŽ ååã
æããã¢ã«ã³ãã·åºã«ãã€ãŠãïŒãïŒåã®ççŽ å
åãæããã·ã¯ãã¢ã«ãã«åºã«ãã€ãŠãããã¯ã¢
ããã³ãã«åºã«ãã€ãŠçœ®æãããŠããçŽéããã
ã¯æåãç¶ã®ïŒãïŒåã®ççŽ ååãæããã¢ã«ã
ã«åºãè¡šãããããããã¯åºââCR3R4R5ãå ±å
ããŠïŒãïŒåã®ççŽ ååãæããã·ã¯ãã¢ã«ãã«
åºãããã¯ã¢ããã³ãã«åºã圢æããïŒãæãã
åºãè¡šãããã¯ãã©ã³ã¹âããã¬ã³ãããã¯ãš
ãã¬ã³åºãè¡šãããã¯ã«ã«ããã«åºãããã¯äž
è¬åŒ ïŒåŒäžR6ã¯æ°ŽçŽ ååãããã¯çŽéãããã¯æ
åãç¶ã®ïŒãïŒåã®ççŽ ååãæããã¢ã«ãã«åº
ãè¡šãããR7ã¯æ°ŽçŽ ååãããã¯ã«ã«ãã³é žã¢
ã·ã«åºãè¡šããïŒãæããåºã§ãããããããã¯
ãããªããã° (ii) R2ã¯äžè¬åŒ âââR8 ïŒåŒäžïŒ¡ã¯çŽéãããã¯æåãç¶ã®ïŒã12åã®
ççŽ ååãæããã¢ã«ãã¬ã³éãè¡šãããã¯çŽ
æ¥ã®çµåãè¡šããããããã¯é žçŽ ãããã¯ç¡«é»å
åãè¡šããããããŠR8ã¯äŸãã°ãããã²ã³å
åãçŽéãããã¯æåãç¶ã®ïŒãïŒåã®ççŽ åå
ãæããã¢ã«ãã«ããã³ã¢ã«ã³ãã·åºãããã³ã
ãªããã¡ãã«åºäŸãã°ããªãã«ãªã«ã¡ãã«åºãã
æã矀ããéžæããã眮æåºã®ïŒåãããã¯ãã
以äžã«ãã眮æããããã¢ãªãŒã«ãããã¯è€çŽ ç°
åºãè¡šããïŒãæããåºãè¡šãããåŒã«ããã
ã¯ãšãã¬ã³ãããã¯ãã©ã³ã¹âããã¬ã³åºãè¡š
ãããåŒã«ãããã¯ã«ã«ããã«åºãããã¯åŒ
ïŒåŒäžR6ããã³R7ã¯åèšã®æå³ãæããïŒã
æããåºãè¡šãããããããã¯ãããªããã° (iii) R2ã¯åèšã®åºR8ãè¡šããããããŠåŒã«ã
ããããã³ïŒ¹ã¯åæã«ãšãã¬ã³ããã³ã«ã«ãã
ã«ããã©ã³ã¹âããã¬ã³ããã³ã«ã«ããã«ããã
ãã¯ãšãã¬ã³ããã³âCHïŒOR7ïŒâåºïŒR7ã¯åèš
ã®ãšããã§ããïŒãããããè¡šããã
åèšã®æ现æžã«ãããŠãäžè¬åŒã«ãããŠç€ºã
ããæ§é ã¯å°ããšãïŒåã®ãã©ãªãã€ãŒäžå¿ãæ
ããŠããããããïŒåã®ãã©ãªãã€ãŒäžå¿ã¯åŽé
âïŒCH2ïŒ7OR1ããã³âââR2ãçµåããŠã
ãç°ççŽ ååã«ããããšãææãããŠããããã
ãã®ïŒåã®ãã©ãªãã€ãŒäžå¿ã«å ããŠãããã«ïŒ
ã€ã®ãã©ãªãã€âäžå¿ããåŒãæããåºãè¡š
ããå Žåã«çãããããŠãªãããã«ä»ã®ãã©ãªã
ã€ãŒäžå¿ãåºR1ããã³R2äžã«çããã§ãããã
ãã©ãªãã€ãŒäžå¿ã®ååšã¯ãããç¥ãããŠããã
ãã«ç°æ§äœã®ååšãå°ããããããªãããåŒã
æããååç©ã¯ãã¹ãŠè©²ç°ççŽ ååã«çµåããŠã
ã該åŽéâïŒCH2ïŒ7OR1ããã³âââR2ãçž
äºã«ãã©ã³ã¹é 眮ã§ãããããªé 眮ãæããããš
ããã³ãã©ã³ã¹é 眮ã§ç°ççŽ ååã«çµåããŠãã
該åŽéâïŒCH2ïŒ7OR1ããã³âââR2ãæã
ãäžè¬åŒã®ãã¹ãŠã®ç°æ§äœããã³ãããã®æ··å
ç©ãåèšã®æ现æžã«èšèŒãããŠããçºæã®ç¯å²å
ã§ããããšãåèšã®æ现æžã«èšèŒãããŠããã
ããæ§é ã¯å°ããšãïŒåã®ãã©ãªãã€ãŒäžå¿ãæ
ããŠããããããïŒåã®ãã©ãªãã€ãŒäžå¿ã¯åŽé
âïŒCH2ïŒ7OR1ããã³âââR2ãçµåããŠã
ãç°ççŽ ååã«ããããšãææãããŠããããã
ãã®ïŒåã®ãã©ãªãã€ãŒäžå¿ã«å ããŠãããã«ïŒ
ã€ã®ãã©ãªãã€âäžå¿ããåŒãæããåºãè¡š
ããå Žåã«çãããããŠãªãããã«ä»ã®ãã©ãªã
ã€ãŒäžå¿ãåºR1ããã³R2äžã«çããã§ãããã
ãã©ãªãã€ãŒäžå¿ã®ååšã¯ãããç¥ãããŠããã
ãã«ç°æ§äœã®ååšãå°ããããããªãããåŒã
æããååç©ã¯ãã¹ãŠè©²ç°ççŽ ååã«çµåããŠã
ã該åŽéâïŒCH2ïŒ7OR1ããã³âââR2ãçž
äºã«ãã©ã³ã¹é 眮ã§ãããããªé 眮ãæããããš
ããã³ãã©ã³ã¹é 眮ã§ç°ççŽ ååã«çµåããŠãã
該åŽéâïŒCH2ïŒ7OR1ããã³âââR2ãæã
ãäžè¬åŒã®ãã¹ãŠã®ç°æ§äœããã³ãããã®æ··å
ç©ãåèšã®æ现æžã«èšèŒãããŠããçºæã®ç¯å²å
ã§ããããšãåèšã®æ现æžã«èšèŒãããŠããã
åèšã®æ现æžã«ãããŠãåŒã®ååç©ã䟡å€ã
ãè¬çåŠçæ§è³ªãäŸãã°èé žåæ³æå¶ãäœè¡å§ç
ã®çæãæ°ç®¡æ¯æ¡åŒµãåå®®åçž®ã®åºæ¿ãäœã³ã¬ã¹
ãããŒã«è¡çããã³äœèè¡ççæãããã³é»äœå
解ïŒluteolysisïŒåºæ¿ãå å«ãããäŸãã°ããã¹
ã¿ã°ã©ã³ãžã³ãšããŠç¥ãããŠãã倩ç¶çæç©ã®é¢
é£ç³»åã«å žåçãªæ§è³ªãæããããšãèšèŒãããŠ
ããã
ãè¬çåŠçæ§è³ªãäŸãã°èé žåæ³æå¶ãäœè¡å§ç
ã®çæãæ°ç®¡æ¯æ¡åŒµãåå®®åçž®ã®åºæ¿ãäœã³ã¬ã¹
ãããŒã«è¡çããã³äœèè¡ççæãããã³é»äœå
解ïŒluteolysisïŒåºæ¿ãå å«ãããäŸãã°ããã¹
ã¿ã°ã©ã³ãžã³ãšããŠç¥ãããŠãã倩ç¶çæç©ã®é¢
é£ç³»åã«å žåçãªæ§è³ªãæããããšãèšèŒãããŠ
ããã
ããã«åºç¯ãªç 究ãšå®éšã®çµæãR1ãæ°ŽçŽ å
åãR2ãåŒãåŒäžïŒ¡ã¯ã¡ãã¬ã³åºïŒããªãã¡
ãã ïŒåã®ççŽ ååãæããã¢ã«ãã¬ã³éïŒãè¡š
ãããã¯é žçŽ ååããããŠR8ã¯ããšãã«åºã
è¡šããããæããåºã§ãããããšãã¬ã³åºãè¡š
ãããããŠïŒ¹ãã«ã«ããã«åºãè¡šããåŒã®åå
ç©ã¯åªããæçšæ§ãæããããšãç¹ã«ãæãŸãã
ãã¬å¯äœçšäŸãã°äžç¢ãæ¹ãèµ·ãäœçšã䌎ãããš
ãç°åžžã«äœããè朰çããã³èé žéå€çã®é²æ¢ã
ããã¯æ²»çã«ãããæçšæ§ãæããããšãä»ãèŠ
åºãããã
åãR2ãåŒãåŒäžïŒ¡ã¯ã¡ãã¬ã³åºïŒããªãã¡
ãã ïŒåã®ççŽ ååãæããã¢ã«ãã¬ã³éïŒãè¡š
ãããã¯é žçŽ ååããããŠR8ã¯ããšãã«åºã
è¡šããããæããåºã§ãããããšãã¬ã³åºãè¡š
ãããããŠïŒ¹ãã«ã«ããã«åºãè¡šããåŒã®åå
ç©ã¯åªããæçšæ§ãæããããšãç¹ã«ãæãŸãã
ãã¬å¯äœçšäŸãã°äžç¢ãæ¹ãèµ·ãäœçšã䌎ãããš
ãç°åžžã«äœããè朰çããã³èé žéå€çã®é²æ¢ã
ããã¯æ²»çã«ãããæçšæ§ãæããããšãä»ãèŠ
åºãããã
ããªãã¡ãæ¬çºæã¯åŒ
ïŒåŒäžïŒåã®åŽéã¯ç°ççŽ ååã«ãã©ã³ã¹é
眮
ã«ãŠçµåããŠããïŒ ãæããååç©ãããªãã¡ïŒâããããã·ã¡ãã«
â16âããšããã·â15âãªããœâ13ïŒ14âãžãã
ãâïŒâãã«ã«ããã·â11ïŒ15âãžããªãã·â
17ïŒ18ïŒ19ïŒ20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³
E1ããã³ãã®é¡åç°æ§äœãªãã³ã«ãããã®æ··å
ç©ãæäŸãããã®ã§ããã
ã«ãŠçµåããŠããïŒ ãæããååç©ãããªãã¡ïŒâããããã·ã¡ãã«
â16âããšããã·â15âãªããœâ13ïŒ14âãžãã
ãâïŒâãã«ã«ããã·â11ïŒ15âãžããªãã·â
17ïŒ18ïŒ19ïŒ20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³
E1ããã³ãã®é¡åç°æ§äœãªãã³ã«ãããã®æ··å
ç©ãæäŸãããã®ã§ããã
ç¹ã«éèŠãªåŒã®ååç©ã®æ··åç©ã¯ïŒçš®ã®é¡å
ç°æ§åœ¢ãçããå²åã§ååšããŠãããã®ãããªã
ã¡ïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âããšãã
ã·â15âãªããœâ13ïŒ14âãžãããâïŒâãã«ã«
ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ20â
ããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ã§ããã
ç°æ§åœ¢ãçããå²åã§ååšããŠãããã®ãããªã
ã¡ïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âããšãã
ã·â15âãªããœâ13ïŒ14âãžãããâïŒâãã«ã«
ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ20â
ããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ã§ããã
åŒãæããååç©ããã³ãã®æ··åç©ã¯äžè¬åŒ
ã®ç¯å²å ã«å å«ããããããããã¯åŸæ¥è©³çŽ°ã«
èšèŒãããã¯ç¹æ§åãããŠã¯ããªãã
ã®ç¯å²å ã«å å«ããããããããã¯åŸæ¥è©³çŽ°ã«
èšèŒãããã¯ç¹æ§åãããŠã¯ããªãã
å®éšå®€èŠæš¡ã®ãã¹ãã«ãããŠã
(i) ã©ããã«ãããèé
žåæ³æžå°ã
(ii) ã€ã³ãã¡ã¿ã·ã³ãçšããåŠçã«ããã©ããã«
èªèµ·ãããè朰çãžã®æ®æãããã³ (ii) ã¢ã«ãããçšããåŠçã«ããã©ããã«èªèµ·ã
ãã䟿ç§ã®åŸæïŒååç©ãæãŸãããã¬äžç¢ãª
ãå¯äœçšãçããå¯èœæ§ã®ææšïŒ ã«ãããïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âã
ãšããã·â15âãªããœâ13ïŒ14âãžãããâïŒâ
ãã«ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ
19ïŒ20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ã®æŽ»
æ§åºŠã枬å®ãããã
èªèµ·ãããè朰çãžã®æ®æãããã³ (ii) ã¢ã«ãããçšããåŠçã«ããã©ããã«èªèµ·ã
ãã䟿ç§ã®åŸæïŒååç©ãæãŸãããã¬äžç¢ãª
ãå¯äœçšãçããå¯èœæ§ã®ææšïŒ ã«ãããïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âã
ãšããã·â15âãªããœâ13ïŒ14âãžãããâïŒâ
ãã«ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ
19ïŒ20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ã®æŽ»
æ§åºŠã枬å®ãããã
以äžã«ç€ºãããED50å€ã¯ãããã察ç
§ã®50ïŒ
ãŸã§èé žåæ³ãæžå°ãããè朰çã«å¯ŸããŠæ®æ
ãããããŠäŸ¿ç§ãå æããã®ã«å¿ èŠãªå¹³åçµå£è¬
çšéã®çè«å€ãšããŠèŠå®ãããã
ãŸã§èé žåæ³ãæžå°ãããè朰çã«å¯ŸããŠæ®æ
ãããããŠäŸ¿ç§ãå æããã®ã«å¿ èŠãªå¹³åçµå£è¬
çšéã®çè«å€ãšããŠèŠå®ãããã
ED50ã®çµæã¯æ¬¡ã®ãšããã§ããã
(i) 0.010ã0.015mgïŒåç©ã®äœéKgã
(ii) 0.02mgïŒåç©ã®äœéKgãããã³
(iii) 3.5mgïŒåç©ã®äœéKgã
ãããã®çµæã¯ãèé
žåæ³æžå°ãšè朰çãžã®æ®
æã«å¿ èŠãšãããçšéã䟿ç§ãåŸæããã®ã«å¿ èŠ
ãšãããçšéããã¯ããã«äœãããšã瀺ããŠã
ããããæ ãæ¬çºæååç©ã¯ãç¹ã«çµå£çµè·¯ã«ã
ãæäžãããå Žåã«äžç¢ãã»ãšãã©ãããã¯äœã
䌎ãªãããšãªãè朰çããã³èé žéå€çã軜æžã
ãéã§æ£è ã«æäžããããã
æã«å¿ èŠãšãããçšéã䟿ç§ãåŸæããã®ã«å¿ èŠ
ãšãããçšéããã¯ããã«äœãããšã瀺ããŠã
ããããæ ãæ¬çºæååç©ã¯ãç¹ã«çµå£çµè·¯ã«ã
ãæäžãããå Žåã«äžç¢ãã»ãšãã©ãããã¯äœã
䌎ãªãããšãªãè朰çããã³èé žéå€çã軜æžã
ãéã§æ£è ã«æäžããããã
åŒãæããååç©ãåèšã®ç¹èš±æ现æžã«èšèŒ
ãããŠããé¢é£ååç©ãšæ¯èŒããå ŽåãåŒã®å
åç©ã¯è朰çããã³èé žéå€çã®æ²»çã«ãããŠäž
ç¢ãã»ãšãã©ãããã¯å šã䌎ãªãããšãªããããŠ
æãŸãããã¬åå®®åçž®ã䌎ãªãããšãªãåèšã®æ¢
ç¥ååç©ãããéèŠãã€äºæãããªãã€ãå©ç¹ã
æããããšãèŠåºãããã
ãããŠããé¢é£ååç©ãšæ¯èŒããå ŽåãåŒã®å
åç©ã¯è朰çããã³èé žéå€çã®æ²»çã«ãããŠäž
ç¢ãã»ãšãã©ãããã¯å šã䌎ãªãããšãªããããŠ
æãŸãããã¬åå®®åçž®ã䌎ãªãããšãªãåèšã®æ¢
ç¥ååç©ãããéèŠãã€äºæãããªãã€ãå©ç¹ã
æããããšãèŠåºãããã
åèšãšåæ§ã®å®éšå®€ææš¡ã®ãã¹ãã«ãããŠãã
ããå©ç¹ã¯åèšã®æ现æžã«èšèŒãããŠããäžèšã®
ïŒçš®ã®æ¯èŒååç©ã«ã€ããŠç«èšŒãããã
ããå©ç¹ã¯åèšã®æ现æžã«èšèŒãããŠããäžèšã®
ïŒçš®ã®æ¯èŒååç©ã«ã€ããŠç«èšŒãããã
 ïŒâãïŒâïŒïŒâããããã·âïŒâããšãã
ã·ããâãã©ã³ã¹âïŒâãšãã«ïŒâïŒâãªããœ
ã·ã¯ããã³ãã«ãâããã¿ããŒã«ã  ïŒâãïŒâïŒïŒâã¡ãã«âïŒâãªããœãªã¯ã
âãã©ã³ã¹âïŒâãšãã«ïŒâïŒâãªããœã·ã¯ã
ãã³ãã«ãâããã¿ããŒã«ã  ïŒâãïŒâïŒïŒâãªããœâïŒâããšãã«ãã³
ãâãã©ã³ã¹âïŒâãšãã«ïŒâïŒâãªããœã·ã¯
ããã³ãã«ãâããã¿ããŒã«ããã㳠 ïŒâãïŒâïŒïŒâãªããœâïŒâããšãã«ãã
âãã©ã³ã¹âïŒâãšãã«ïŒâïŒâãªããœã·ã¯ã
ãã³ãã«ãâããã¿ããŒã«ã
ã·ããâãã©ã³ã¹âïŒâãšãã«ïŒâïŒâãªããœ
ã·ã¯ããã³ãã«ãâããã¿ããŒã«ã  ïŒâãïŒâïŒïŒâã¡ãã«âïŒâãªããœãªã¯ã
âãã©ã³ã¹âïŒâãšãã«ïŒâïŒâãªããœã·ã¯ã
ãã³ãã«ãâããã¿ããŒã«ã  ïŒâãïŒâïŒïŒâãªããœâïŒâããšãã«ãã³
ãâãã©ã³ã¹âïŒâãšãã«ïŒâïŒâãªããœã·ã¯
ããã³ãã«ãâããã¿ããŒã«ããã㳠 ïŒâãïŒâïŒïŒâãªããœâïŒâããšãã«ãã
âãã©ã³ã¹âïŒâãšãã«ïŒâïŒâãªããœã·ã¯ã
ãã³ãã«ãâããã¿ããŒã«ã
åŒç
§æåãããã¯æ¬æ现æžäžäŸ¿å®äžé
眮ããããã®ã§ãããåæ§ã«ãåŒãæããé¡å
ç°æ§äœã®ïŒÂ±ïŒâæ··åç©ã¯åŒç §æåãä»ãã
ãã
眮ããããã®ã§ãããåæ§ã«ãåŒãæããé¡å
ç°æ§äœã®ïŒÂ±ïŒâæ··åç©ã¯åŒç §æåãä»ãã
ãã
å®éšå®€ãã¹ãã«ãããŠã
ïŒ ååç©ïŒµã¯ååç©ïŒ¡ã®æå¹éãã20åå€ãçµ
å£å®¹éãæäžãããå Žåã«ã©ããã«å¯ŸããŠãã
ããªèé žåæ³æžå°ããçããªãã
å£å®¹éãæäžãããå Žåã«ã©ããã«å¯ŸããŠãã
ããªèé žåæ³æžå°ããçããªãã
ïŒ ååç©ïŒ¶ããã³ïŒ·ã¯ååç©ïŒ¡ã®æå¹éã®50å
å€ãçµå£çšéã§æäžãããå Žåã«ã©ããã«ãã
ãŠã€ã³ãã¡ã¿ã·ã³âèªçºè朰çã®çºçŸãé»æ¢ã§
ããªãã€ãã
å€ãçµå£çšéã§æäžãããå Žåã«ã©ããã«ãã
ãŠã€ã³ãã¡ã¿ã·ã³âèªçºè朰çã®çºçŸãé»æ¢ã§
ããªãã€ãã
ïŒ ååç©ïŒŽã¯ã©ããã«ãããèé
žæŽ»æ§æžå°ã«ã
ããŠããã³ã©ããã®ã€ã³ãã¡ã¿ã·ã³âèªçºè朰
çãžã®æ®æã«ãããŠååç©ïŒ¡ã®ãããšåãæ°Žæº
ã®çµå£æŽ»æ§ã瀺ããããååç©ïŒŽã¯åå®®åçž®åº
æ¿ã«ãããŠååç©ïŒ¡ã®10å掻æ§ã§ãã€ããèé ž
éå€ãããã¯è朰çãæ²»çãããŠããæ£è ã«ãš
ã€ãŠèšç»ã«ãªãåå®®åçž®åºæ¿ã¯ãããã®å Žåã«
ãããŠãæãŸããªãããšãç解ãããã§ãã
ãã
ããŠããã³ã©ããã®ã€ã³ãã¡ã¿ã·ã³âèªçºè朰
çãžã®æ®æã«ãããŠååç©ïŒ¡ã®ãããšåãæ°Žæº
ã®çµå£æŽ»æ§ã瀺ããããååç©ïŒŽã¯åå®®åçž®åº
æ¿ã«ãããŠååç©ïŒ¡ã®10å掻æ§ã§ãã€ããèé ž
éå€ãããã¯è朰çãæ²»çãããŠããæ£è ã«ãš
ã€ãŠèšç»ã«ãªãåå®®åçž®åºæ¿ã¯ãããã®å Žåã«
ãããŠãæãŸããªãããšãç解ãããã§ãã
ãã
åŒãæããååç©ããã³ãã®æ··åç©ã¯äžè¬åŒ
ãæããååç©è£œé ã®ããã®åèšã®æ现æžã«èš
èŒãããŠããæ¹æ³ãé©çšããããããã¯é©åãã
ãããšã«ãã補é ããããã
ãæããååç©è£œé ã®ããã®åèšã®æ现æžã«èš
èŒãããŠããæ¹æ³ãé©çšããããããã¯é©åãã
ãããšã«ãã補é ããããã
åŸã€ãŠãäžè¬åŒãæããååç©ã¯åŒ
ãæãã察å¿ããååç©äžã®ççŽ âççŽ äºéçµ
åããã«ã«ããã«åºã«å¯ŸããŠèªãããã»ã©ã®åœ±é¿
ãåãŒããªãæ¡ä»¶äžãäŸãã°è§ŠåªäŸãã°æšçäžã®
ããžãŠã ãããã¯æšçäžã®ãã©ãžãŠã ã®ååšäžäž
掻æ§ææ©æº¶åªäŸãã°ïŒãïŒåã®ççŽ ååãæãã
ã¢ã«ã«ããŒã«äŸãã°ãšã¿ããŒã«ã®ååšäžã«æ°ŽçŽ æ·»
å ããããšã«ããéå ããŠè£œé ããããæ°ŽçŽ æ·»å
ã¯å¥œéœåã«ã¯åšå²æž©åºŠã§ãããŠé«ããããå§åäž
äŸãã°æ°ŽçŽ å§0.5ã10KgïŒcm2ã«ãŠè¡ããåŸãã
åããã«ã«ããã«åºã«å¯ŸããŠèªãããã»ã©ã®åœ±é¿
ãåãŒããªãæ¡ä»¶äžãäŸãã°è§ŠåªäŸãã°æšçäžã®
ããžãŠã ãããã¯æšçäžã®ãã©ãžãŠã ã®ååšäžäž
掻æ§ææ©æº¶åªäŸãã°ïŒãïŒåã®ççŽ ååãæãã
ã¢ã«ã«ããŒã«äŸãã°ãšã¿ããŒã«ã®ååšäžã«æ°ŽçŽ æ·»
å ããããšã«ããéå ããŠè£œé ããããæ°ŽçŽ æ·»å
ã¯å¥œéœåã«ã¯åšå²æž©åºŠã§ãããŠé«ããããå§åäž
äŸãã°æ°ŽçŽ å§0.5ã10KgïŒcm2ã«ãŠè¡ããåŸãã
åŒãæããååç©ã¯åŒ
ãæãã察å¿ããååç©ã®å æ°Žå解ã«ãã補é ã
ããã
ããã
äžèšã®å æ°Žå解ã¯äžè¬ã«é
žæ§æ¡ä»¶äžäŸãã°åžç¡
æ©é žäŸãã°åžå¡©é žãšå¥œãŸããã¯å®€æž©ä»¥äžäŸãã°50
ã70âã§åå¿ãããããšã«ããããããã¯æ°Žã®å
åšäžææ©é žãçšããŠãäŸãã°é ¢é žæ°Žæº¶æ¶²äŸãã°40
ã80ïŒ ïœïŒïœé ¢é žæ°Žæº¶æ¶²ããããã¯å°éã®æ°Žãå«
æããŠããã¢ã»ãã³äžã®ïœâãã«ãšã³ã¹ã«ãã³é ž
ãïŒâã100âãããã«ç¹ã«15âã30âã®æž©åºŠã§
çšããããšã«ããè¡ããããå¥æ³ãšããŠãåŒã
æããååç©ã奜ãŸããã¯ææ©é žäŸãã°æ°·é ¢é žã
ããã¯ãé žãå«æããŠãã溶é¢å€ã䜿çšããã¯ã
ããã°ã©ãã€ãŒã«ä»ãããšã«ããåŒãæããå
åç©ã«å€æãããããã®æ¹æ³ã«ããã°å æ°Žå解ãš
åæã«ç²Ÿè£œãè¡ãããã
æ©é žäŸãã°åžå¡©é žãšå¥œãŸããã¯å®€æž©ä»¥äžäŸãã°50
ã70âã§åå¿ãããããšã«ããããããã¯æ°Žã®å
åšäžææ©é žãçšããŠãäŸãã°é ¢é žæ°Žæº¶æ¶²äŸãã°40
ã80ïŒ ïœïŒïœé ¢é žæ°Žæº¶æ¶²ããããã¯å°éã®æ°Žãå«
æããŠããã¢ã»ãã³äžã®ïœâãã«ãšã³ã¹ã«ãã³é ž
ãïŒâã100âãããã«ç¹ã«15âã30âã®æž©åºŠã§
çšããããšã«ããè¡ããããå¥æ³ãšããŠãåŒã
æããååç©ã奜ãŸããã¯ææ©é žäŸãã°æ°·é ¢é žã
ããã¯ãé žãå«æããŠãã溶é¢å€ã䜿çšããã¯ã
ããã°ã©ãã€ãŒã«ä»ãããšã«ããåŒãæããå
åç©ã«å€æãããããã®æ¹æ³ã«ããã°å æ°Žå解ãš
åæã«ç²Ÿè£œãè¡ãããã
åŒãæããååç©ã®è£œé ã¯åèšã®æ现æžã«è©³
现ã«èšèŒãããŠããã
现ã«èšèŒãããŠããã
åœæ¥è
ã«ãã容æã«èªèãããããšããäžèšã®
ãã©ãªãã€ãŒäžå¿ããçããæ¬çºæååç©ã®é¡å
ç°æ§åœ¢æ ã¯æ¢ç¥ã®æ¹æ³ãé©çšãããã¯é©åããã
ããšã«ããåé¢ããããã
ãã©ãªãã€ãŒäžå¿ããçããæ¬çºæååç©ã®é¡å
ç°æ§åœ¢æ ã¯æ¢ç¥ã®æ¹æ³ãé©çšãããã¯é©åããã
ããšã«ããåé¢ããããã
æ¬æ现æžã§çšããããŠãããæ¢ç¥ã®æ¹æ³ããªã
çšèªã¯éå»ã«äœ¿çšãããã¯æç®äžã«èšèŒãããŠã
ãæ¹æ³ãæå³ããã
çšèªã¯éå»ã«äœ¿çšãããã¯æç®äžã«èšèŒãããŠã
ãæ¹æ³ãæå³ããã
以äžã®å®æœäŸã«ããæ¬çºæã説æããã
å®æœäŸ ïŒ
(i) ïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âããšã
ãã·â15âãªããœâ13ïŒ14âãžãããâïŒâã
ã«ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ
19ïŒ20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1 ãšã¿ããŒã«ïŒ25mlïŒäžã®ïŒÂ±ïŒâïŒâãããã
ã·ã¡ãã«â16âããšããã·â15âãªããœâïŒâã
ã«ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ
20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ïŒ350mgïŒ
ã®æº¶æ¶²ãæšçäžã®ãã©ãžãŠã 觊åªïŒïŒïŒ ïœïŒïœïŒ
ã®ååšäžå®€æž©ããã³æ°ŽçŽ å§4.9KgïŒcm2ã«ãããŠæ°Ž
çŽ æ·»å ããã次ãã§ãã®æ··åç©ãããããåã§
éã液ãç空äžèžçºããããçããæ®çåãã·
ãªã«åžçå€äžã溶é¢å€ãšããŠé ¢é žãšãã«ãã·ã¯ã
ãããµã³ããã³90ïŒ ïœïŒïœãé žæ°Žæº¶æ¶²ïŒ40ïŒ40ïŒ
ïŒå®¹éæ¯ïŒãããªãæ··åç©ãçšããŠãã¬ãã©ãã€
ãŽèå±€ã¯ãããã°ã©ãã€ãŒã«ãã粟補ããŠïŒÂ±ïŒ
âïŒâããããã·ã¡ãã«â16âããšããã·â15â
ãªããœâ13ïŒ14âãžãããâïŒâãã«ã«ããã·â
11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ20âããã©ã
ã«ããã¹ã¿ã°ã©ã³ãžã³E1ïŒ85mgïŒãåŸããå çŽ
åæå€ïŒå®æž¬å€C72.8ãH9.0ïŒ ãC22H32O4ã«å¯Ÿã
ãèšç®å€C73.3ãH8.9ïŒ ãèµ€å€ç·åžåã¹ãã¯ã
ã«ïŒÎœ3450ã1740ã750ã690cm-1ãæ žç£æ°å ±é³Žã¹
ãã¯ãã«ïŒCDCl3ïŒïŒ1.1ã2.9ÎŽïŒãã«ããã¬ã
ãïŒã3.6ÎŽïŒããªãã¬ããïŒã4.6ÎŽïŒã·ã³ã°ã¬ã
ãïŒã6.8ã7.5ÎŽïŒãã«ããã¬ããïŒãã
ãã·â15âãªããœâ13ïŒ14âãžãããâïŒâã
ã«ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ
19ïŒ20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1 ãšã¿ããŒã«ïŒ25mlïŒäžã®ïŒÂ±ïŒâïŒâãããã
ã·ã¡ãã«â16âããšããã·â15âãªããœâïŒâã
ã«ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ
20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ïŒ350mgïŒ
ã®æº¶æ¶²ãæšçäžã®ãã©ãžãŠã 觊åªïŒïŒïŒ ïœïŒïœïŒ
ã®ååšäžå®€æž©ããã³æ°ŽçŽ å§4.9KgïŒcm2ã«ãããŠæ°Ž
çŽ æ·»å ããã次ãã§ãã®æ··åç©ãããããåã§
éã液ãç空äžèžçºããããçããæ®çåãã·
ãªã«åžçå€äžã溶é¢å€ãšããŠé ¢é žãšãã«ãã·ã¯ã
ãããµã³ããã³90ïŒ ïœïŒïœãé žæ°Žæº¶æ¶²ïŒ40ïŒ40ïŒ
ïŒå®¹éæ¯ïŒãããªãæ··åç©ãçšããŠãã¬ãã©ãã€
ãŽèå±€ã¯ãããã°ã©ãã€ãŒã«ãã粟補ããŠïŒÂ±ïŒ
âïŒâããããã·ã¡ãã«â16âããšããã·â15â
ãªããœâ13ïŒ14âãžãããâïŒâãã«ã«ããã·â
11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ20âããã©ã
ã«ããã¹ã¿ã°ã©ã³ãžã³E1ïŒ85mgïŒãåŸããå çŽ
åæå€ïŒå®æž¬å€C72.8ãH9.0ïŒ ãC22H32O4ã«å¯Ÿã
ãèšç®å€C73.3ãH8.9ïŒ ãèµ€å€ç·åžåã¹ãã¯ã
ã«ïŒÎœ3450ã1740ã750ã690cm-1ãæ žç£æ°å ±é³Žã¹
ãã¯ãã«ïŒCDCl3ïŒïŒ1.1ã2.9ÎŽïŒãã«ããã¬ã
ãïŒã3.6ÎŽïŒããªãã¬ããïŒã4.6ÎŽïŒã·ã³ã°ã¬ã
ãïŒã6.8ã7.5ÎŽïŒãã«ããã¬ããïŒãã
以äžã®(ii)ããã³(iii)ã«ãããŠåèš(i)ã®åºçºç©è³ªã®
補æ³ãè¿°ã¹ãã
補æ³ãè¿°ã¹ãã
(ii) ïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âããšã
ãã·â15âãªããœâïŒâãã«ã«ããã·â11ïŒ15
âãžããªãã·â17ïŒ18ïŒ19ïŒ20âããã©ãã«ã
ãã¹ã¿ã°ã©ã³ãžã³E1 ïŒâïŒïŒâããããã·ãããã«ïŒâïŒâïŒïŒâ
ãªããœâïŒâããšããã·ããâãã©ã³ã¹âïŒâãš
ãã«ïŒâïŒïŒïŒâãžãªããµã¹ãããïŒïŒïŒããã
ã³ïŒ400mgïŒãé ¢é žæ°Žæº¶æ¶²ïŒ20mlã50ïŒ ïœïŒïœïŒã
ãã³ããã©ããããã©ã³ïŒ10mlïŒããæãæ··åç©
ã40âã§ïŒæéæ¹æããã次ãã§æº¶åªãç空äžèž
çºãããæ®çåãã溶é¢å€ãšããŠé ¢é žãšãã«ãã·
ã¯ããããµã³ããã³90ïŒ ïœïŒïœãé žæ°Žæº¶æ¶²ãããª
ãæ··åç©ïŒ40ïŒ40ïŒïŒã容éæ¯ïŒãçšãããã·ãª
ã«åžçå€äžã®ãã¬ãã©ãã€ãŽèå±€ã¯ãããã°ã©ã
ã€ãŒã«ãã粟補ããããšã«ããïŒÂ±ïŒâïŒâãã
ããã·ã¡ãã«â16âããšããã·â15âãªããœâïŒ
âãã«ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ
19ïŒ20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ïŒ67
mgïŒãåŸãããããå çŽ åæå€ïŒå®æž¬å€C73.7ã
H8.8ïŒ ãC22H30O4ã®èšç®å€C73.7ãH8.4ïŒ ãèµ€å€
ç·åžåã¹ãã¯ãã«Îœ3450ã1740ã1690ã750ã690
cm-1ãã
ãã·â15âãªããœâïŒâãã«ã«ããã·â11ïŒ15
âãžããªãã·â17ïŒ18ïŒ19ïŒ20âããã©ãã«ã
ãã¹ã¿ã°ã©ã³ãžã³E1 ïŒâïŒïŒâããããã·ãããã«ïŒâïŒâïŒïŒâ
ãªããœâïŒâããšããã·ããâãã©ã³ã¹âïŒâãš
ãã«ïŒâïŒïŒïŒâãžãªããµã¹ãããïŒïŒïŒããã
ã³ïŒ400mgïŒãé ¢é žæ°Žæº¶æ¶²ïŒ20mlã50ïŒ ïœïŒïœïŒã
ãã³ããã©ããããã©ã³ïŒ10mlïŒããæãæ··åç©
ã40âã§ïŒæéæ¹æããã次ãã§æº¶åªãç空äžèž
çºãããæ®çåãã溶é¢å€ãšããŠé ¢é žãšãã«ãã·
ã¯ããããµã³ããã³90ïŒ ïœïŒïœãé žæ°Žæº¶æ¶²ãããª
ãæ··åç©ïŒ40ïŒ40ïŒïŒã容éæ¯ïŒãçšãããã·ãª
ã«åžçå€äžã®ãã¬ãã©ãã€ãŽèå±€ã¯ãããã°ã©ã
ã€ãŒã«ãã粟補ããããšã«ããïŒÂ±ïŒâïŒâãã
ããã·ã¡ãã«â16âããšããã·â15âãªããœâïŒ
âãã«ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ
19ïŒ20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ïŒ67
mgïŒãåŸãããããå çŽ åæå€ïŒå®æž¬å€C73.7ã
H8.8ïŒ ãC22H30O4ã®èšç®å€C73.7ãH8.4ïŒ ãèµ€å€
ç·åžåã¹ãã¯ãã«Îœ3450ã1740ã1690ã750ã690
cm-1ãã
(iii) ïŒâïŒïŒâããããã·ãããã«ïŒâïŒâïŒïŒ
âãªããœâïŒâããšããã·ããâãã©ã³ã¹âïŒ
âãšãã«ïŒâïŒïŒïŒâãžãªããµã¹ãããïŒïŒ
ïŒããã㳠也ç¥ããã©ããããã©ã³ïŒ150mlïŒäžã®ãžã¡ã
ã«ïŒâãªããœâïŒâããšããã·ãããã«ãã¹ãã
ãŒãïŒ43ïœïŒã®æº¶æ¶²ãããã©ããããã©ã³ïŒ200
mlããããªãŠã ã§ä¹Ÿç¥ïŒäžã®æ°ŽçŽ åãããªãŠã
ïŒ3.6ïœïŒã®æ¹ææžæ¿æ¶²äžã«ç©ºçŽ æ°æµã®äžå®€æž©ã§æ»Ž
äžããã枩床ã¯45âã«äžæãããåèšã®æ··åç©ã
30åéæ¹æãã次ãã§ä¹Ÿç¥ããã©ããããã©ã³
ïŒ100mlïŒäžã®ïŒâãã«ãã«âïŒâïŒïŒâãããã
ã·ãããã«â1.4âãžãªããµã¹ãããïŒïŒïŒãã
ãã³ïŒ18.9ïœãç±³åœç¹èš±ç¬¬3880883å·æ现æžã®èš
èŒã®ããã«ããŠè£œé ïŒã®æº¶æ¶²ããã®æ··åç©äžã«43
âã§åŸã ã«å ããããã®æ··åç©ã43ã47âã§ïŒæ
éæ¹æãã次ãã§å·åŽããéãç空äžèžçºãã
ããæ®çåããžãšãã«ãšãŒãã«ïŒ100mlïŒäžã«æº¶
解ããããšãŒãã«æ§æº¶æ¶²ãæ°ŽæŽïŒïŒÃ100mlïŒã
ããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥åŸããšãŒãã«æ§æº¶æ¶²
ãèžçºãããŠè€è²ã®æ²¹ïŒ24.28ïœïŒãåŸãããã
ããã«ããé žã«ã©ã ïŒ250ïœãã¡ã«ã¯ïŒMerckïŒ
ã·ãªã«ã²ã«60ïŒäžããžãšãã«ãšãŒãã«ãçšããŠæº¶
é¢ããã¯ãããã°ã©ãã€ãŒã«ãã粟補ãããšïŒâ
ïŒïŒâããããã·ãããã«ïŒâïŒâïŒïŒâãªããœ
âïŒâããšããã·ããâãã©ã³ã¹âïŒâãšãã«ïŒ
âïŒïŒïŒâãžãªããµã¹ãããïŒïŒïŒãããã³
ïŒ7.88ïœïŒãåŸãããããå çŽ åæå€ïŒå®æž¬å€
C71.8ãH8.7ïŒ ãC24H34O5ã®èšç®å€C71.6ãH8.5
ïŒ ãèµ€å€ç·åžåã¹ãã¯ãã«Îœ3450ã1690ã950ã
750ã690cm-1ãæ žç£æ°å ±é³Žã¹ãã¯ãã«
ïŒCDCl3ïŒïŒ0.8ã2.7ÎŽïŒãã«ããã¬ããïŒã3.5ã
3.8ÎŽïŒããªãã¬ããïŒã3.95ÎŽã4.75ÎŽïŒã·ã³ã°
ã¬ããïŒã6.3ã7.5ÎŽïŒãã«ããã¬ããïŒãã
âãªããœâïŒâããšããã·ããâãã©ã³ã¹âïŒ
âãšãã«ïŒâïŒïŒïŒâãžãªããµã¹ãããïŒïŒ
ïŒããã㳠也ç¥ããã©ããããã©ã³ïŒ150mlïŒäžã®ãžã¡ã
ã«ïŒâãªããœâïŒâããšããã·ãããã«ãã¹ãã
ãŒãïŒ43ïœïŒã®æº¶æ¶²ãããã©ããããã©ã³ïŒ200
mlããããªãŠã ã§ä¹Ÿç¥ïŒäžã®æ°ŽçŽ åãããªãŠã
ïŒ3.6ïœïŒã®æ¹ææžæ¿æ¶²äžã«ç©ºçŽ æ°æµã®äžå®€æž©ã§æ»Ž
äžããã枩床ã¯45âã«äžæãããåèšã®æ··åç©ã
30åéæ¹æãã次ãã§ä¹Ÿç¥ããã©ããããã©ã³
ïŒ100mlïŒäžã®ïŒâãã«ãã«âïŒâïŒïŒâãããã
ã·ãããã«â1.4âãžãªããµã¹ãããïŒïŒïŒãã
ãã³ïŒ18.9ïœãç±³åœç¹èš±ç¬¬3880883å·æ现æžã®èš
èŒã®ããã«ããŠè£œé ïŒã®æº¶æ¶²ããã®æ··åç©äžã«43
âã§åŸã ã«å ããããã®æ··åç©ã43ã47âã§ïŒæ
éæ¹æãã次ãã§å·åŽããéãç空äžèžçºãã
ããæ®çåããžãšãã«ãšãŒãã«ïŒ100mlïŒäžã«æº¶
解ããããšãŒãã«æ§æº¶æ¶²ãæ°ŽæŽïŒïŒÃ100mlïŒã
ããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥åŸããšãŒãã«æ§æº¶æ¶²
ãèžçºãããŠè€è²ã®æ²¹ïŒ24.28ïœïŒãåŸãããã
ããã«ããé žã«ã©ã ïŒ250ïœãã¡ã«ã¯ïŒMerckïŒ
ã·ãªã«ã²ã«60ïŒäžããžãšãã«ãšãŒãã«ãçšããŠæº¶
é¢ããã¯ãããã°ã©ãã€ãŒã«ãã粟補ãããšïŒâ
ïŒïŒâããããã·ãããã«ïŒâïŒâïŒïŒâãªããœ
âïŒâããšããã·ããâãã©ã³ã¹âïŒâãšãã«ïŒ
âïŒïŒïŒâãžãªããµã¹ãããïŒïŒïŒãããã³
ïŒ7.88ïœïŒãåŸãããããå çŽ åæå€ïŒå®æž¬å€
C71.8ãH8.7ïŒ ãC24H34O5ã®èšç®å€C71.6ãH8.5
ïŒ ãèµ€å€ç·åžåã¹ãã¯ãã«Îœ3450ã1690ã950ã
750ã690cm-1ãæ žç£æ°å ±é³Žã¹ãã¯ãã«
ïŒCDCl3ïŒïŒ0.8ã2.7ÎŽïŒãã«ããã¬ããïŒã3.5ã
3.8ÎŽïŒããªãã¬ããïŒã3.95ÎŽã4.75ÎŽïŒã·ã³ã°
ã¬ããïŒã6.3ã7.5ÎŽïŒãã«ããã¬ããïŒãã
å®æœäŸïŒã®ååç©ã®ã¢ã»ããŒãã«ã€ããŠæšæºç
ãªå®éšæäœãçšããŠç®åºãããLD50å€ãäžèšã«
瀺ããã¢ã»ããŒãã¯åã«ããããã®ååç©ã®æäž
ã«å¥œéœåãªåœ¢æ ã§ãããšããçç±ãã䜿çšããã
ãã®ã§ããã身äœã«ãããŠã¯ã¢ã»ããŒãååç©ã¯
å®æœäŸïŒèšèŒã®éé¢ããããã·åºã«å解ãããã
äžèšã®æ°åãåŸãããã
ãªå®éšæäœãçšããŠç®åºãããLD50å€ãäžèšã«
瀺ããã¢ã»ããŒãã¯åã«ããããã®ååç©ã®æäž
ã«å¥œéœåãªåœ¢æ ã§ãããšããçç±ãã䜿çšããã
ãã®ã§ããã身äœã«ãããŠã¯ã¢ã»ããŒãååç©ã¯
å®æœäŸïŒèšèŒã®éé¢ããããã·åºã«å解ãããã
äžèšã®æ°åãåŸãããã
LD50ïŒmgïŒåç©äœéKgïŒ ã©ãã ããŠã¹
çµ å£ 74 14ã27
éèå
3.6 3.7
ãã®è¡šã«èšèŒãããã©ããã®çµå£LD50å€ãæ¬
æ现æžç¬¬11é 第ïŒã13è¡èšèŒã®çµå£ED50å€(i)ã
ãã³(ii)ãšæ¯èŒãããšãçµå£LD50å€ãçµå£ED50å€
ããã¯ããã«å€§ããããšãæããã«å€ããã©ãã
ã«ãããŠèé žåæ³ãæžå°ããããã³è朰çã«æ®æ
ããED50å€ã¯ãããã0.010ã0.015ããã³0.02
mgïŒåç©äœéKgã§ããã欲ãããå¯äœçšã§ããã©
ããã®äŸ¿ç§å æã®ããã®ED50å€ã¯3.5mgïŒåç©äœ
éKgã§ãããè¡šããå€ãããã«ãã©ããã®çµå£
LD50å€ã¯74mgïŒåç©äœéKgã§ããã®ã§ãææã
ããèé žåæ³æžå°ããã³è朰çãžã®æ®æã«é¢ãã
掻æ§ã«ã€ããŠã®ED50å€ãããã©ããã«ãããçµ
å£LD50å€ã¯3700ã7400å倧ããããšãå€æãã
ããããªãã¡å®å šã«äœ¿çšããããç¯å²ãåºããã
ã§ããã
æ现æžç¬¬11é 第ïŒã13è¡èšèŒã®çµå£ED50å€(i)ã
ãã³(ii)ãšæ¯èŒãããšãçµå£LD50å€ãçµå£ED50å€
ããã¯ããã«å€§ããããšãæããã«å€ããã©ãã
ã«ãããŠèé žåæ³ãæžå°ããããã³è朰çã«æ®æ
ããED50å€ã¯ãããã0.010ã0.015ããã³0.02
mgïŒåç©äœéKgã§ããã欲ãããå¯äœçšã§ããã©
ããã®äŸ¿ç§å æã®ããã®ED50å€ã¯3.5mgïŒåç©äœ
éKgã§ãããè¡šããå€ãããã«ãã©ããã®çµå£
LD50å€ã¯74mgïŒåç©äœéKgã§ããã®ã§ãææã
ããèé žåæ³æžå°ããã³è朰çãžã®æ®æã«é¢ãã
掻æ§ã«ã€ããŠã®ED50å€ãããã©ããã«ãããçµ
å£LD50å€ã¯3700ã7400å倧ããããšãå€æãã
ããããªãã¡å®å šã«äœ¿çšããããç¯å²ãåºããã
ã§ããã
æ¬çºæã¯è£œè¬çšæ
äœãããã¯ã³ãŒãã€ã³ã°å€ãš
å ±ã«åŒãæããååç©ããæãè¬å€çµæç©ãã
ã®ç¯å²å ã«å å«ãããèšåºäžã®å®æœã«ãããŠæ¬çº
æååç©ã¯éåžžçµå£çãçµçŽè žçãçµè çããã
ã¯éçµå£çã«æäžãããã
å ±ã«åŒãæããååç©ããæãè¬å€çµæç©ãã
ã®ç¯å²å ã«å å«ãããèšåºäžã®å®æœã«ãããŠæ¬çº
æååç©ã¯éåžžçµå£çãçµçŽè žçãçµè çããã
ã¯éçµå£çã«æäžãããã
çµå£æäžã®ããã®åºäœçµæç©ã«ã¯å§çž®é å€ãäžž
å€ãåæ£ãããç²æ«ãããã³é¡ç²ãå å«ãããã
å€ãåæ£ãããç²æ«ãããã³é¡ç²ãå å«ãããã
çµå£æäžã®ããã®æ¶²äœçµæç©ã«ã¯è£œè¬äžå容ã
ãåŸãä¹³æ¿æ¶²ã溶液ãæžæ¿æ¶²ãã·ãããå€ããã³
ãšãªãã·ãŒã«å€ãå å«ãããã
ãåŸãä¹³æ¿æ¶²ã溶液ãæžæ¿æ¶²ãã·ãããå€ããã³
ãšãªãã·ãŒã«å€ãå å«ãããã
çµå£æäžã®ããã®æ¬çºæã«ããçµæç©ã¯ãŸãã
æ¬çºæååç©ã®ïŒçš®ãããã¯ãã以äžãå«æããŠ
ãããŒã©ãã³ã®ãããªåžåããåŸãç©è³ªã®ã«ãã»
ã«å€ããå å«ããã
æ¬çºæååç©ã®ïŒçš®ãããã¯ãã以äžãå«æããŠ
ãããŒã©ãã³ã®ãããªåžåããåŸãç©è³ªã®ã«ãã»
ã«å€ããå å«ããã
è
æäžã®ããã®åºäœçµæç©ã«ã¯ãããµãªãŒãå
å«ãããã
å«ãããã
çŽè
žæäžã®ããã®åºäœçµæç©ã«ã¯åå€ãå
å«ã
ããã
ããã
éçµå£æäžã®ããã®æ¬çºæã«ãã補å€ã«ã¯æ»
è
æ°Žæ§ãããã¯éæ°Žæ§æº¶æ¶²ãæžæ¿æ¶²ãããã¯ä¹³æ¿æ¶²
ãå å«ãããã
æ°Žæ§ãããã¯éæ°Žæ§æº¶æ¶²ãæžæ¿æ¶²ãããã¯ä¹³æ¿æ¶²
ãå å«ãããã
æ¬çºæååç©ã¯ãŸããæšæºçæäžæ¡ä»¶äžã«ãã
ãŠããèªäœæ°äœç¶ã§ãªãè¬å€ã®åžå ¥ã«ããæäžã«
ã€ããŠèªäœæ¢ç¥ã®ä»»æã®æ¹æ³ã«ããçµå£æäžãã
ãããããªãã¡ãé©åœãªã補å€äžå容ããã溶åª
äŸãã°æ°Žäžã«ããã掻æ§æåã®æº¶æ¶²ã¯æ©æ¢°çåŽé§
åšäŸãã°ã©ã€ãïŒWrightïŒã®åŽé§åšã«ããåŽé§
åãããŠåžå ¥ã«é©ãã埮现ã«åå²ããã液äœç²å
ã®ãšãŒããŸã«ãçæããã掻æ§æåã¯ãŸãèªå·±æš
é²è¬å€çµæç©ããçºçããããšãŒããŸã«ã®åœ¢ã§åž
å ¥ãããããšã«ããçµå£æäžãããŠãããã
ãŠããèªäœæ°äœç¶ã§ãªãè¬å€ã®åžå ¥ã«ããæäžã«
ã€ããŠèªäœæ¢ç¥ã®ä»»æã®æ¹æ³ã«ããçµå£æäžãã
ãããããªãã¡ãé©åœãªã補å€äžå容ããã溶åª
äŸãã°æ°Žäžã«ããã掻æ§æåã®æº¶æ¶²ã¯æ©æ¢°çåŽé§
åšäŸãã°ã©ã€ãïŒWrightïŒã®åŽé§åšã«ããåŽé§
åãããŠåžå ¥ã«é©ãã埮现ã«åå²ããã液äœç²å
ã®ãšãŒããŸã«ãçæããã掻æ§æåã¯ãŸãèªå·±æš
é²è¬å€çµæç©ããçºçããããšãŒããŸã«ã®åœ¢ã§åž
å ¥ãããããšã«ããçµå£æäžãããŠãããã
è¬å€äžæŽ»æ§ãªååç©ã®æäžæ³ã¯åœæ¥äžåšç¥ã§ã
ããããŠé©åœãªããã¯ã«ã¯å»åž«ãè¬å€åž«ãããã¯
ç£å»ã«ãããææã®å¹æãæ£è ã®å€§ããã幎什ã
æ§å¥ããã³ç¶æ³ã®ãããªå åã«äŸãããããŠç£å»
çšäœ¿çšã«éããŠã¯ãæ²»çãããã¹ãåç©ã®çš®é¡ã
ãã³æŽ»æ§ååç©ã®ç©ççæ§è³ªã«äŸã決å®ããã
ããæ¬çºæã®çµæç©ã¯ãŸãåœæ¥çã«ãããŠæ®éã§
ããããã«ãåºäœãããã¯æ¶²äœåžéå€ã湿最å€ã
ä¿åå€ãéŠå³å€ããã³çè²å€çã®ãããªç©è³ªãã
å«æãããã
ããããŠé©åœãªããã¯ã«ã¯å»åž«ãè¬å€åž«ãããã¯
ç£å»ã«ãããææã®å¹æãæ£è ã®å€§ããã幎什ã
æ§å¥ããã³ç¶æ³ã®ãããªå åã«äŸãããããŠç£å»
çšäœ¿çšã«éããŠã¯ãæ²»çãããã¹ãåç©ã®çš®é¡ã
ãã³æŽ»æ§ååç©ã®ç©ççæ§è³ªã«äŸã決å®ããã
ããæ¬çºæã®çµæç©ã¯ãŸãåœæ¥çã«ãããŠæ®éã§
ããããã«ãåºäœãããã¯æ¶²äœåžéå€ã湿最å€ã
ä¿åå€ãéŠå³å€ããã³çè²å€çã®ãããªç©è³ªãã
å«æãããã
æ¬çºæçµæç©äžã®æŽ»æ§æåã®çŸåçã¯å€åãã
ãããææãããæ²»çå¹æã«é©ããè¬çšéãåŸã
ãããããªå²åãæ§æããããšãå¿ èŠã§ãããæ°
åã®åäœæè¬é圢æ ãã»ãŒåæã«æäžããããã
ãšã¯æããã§ããã
ãããææãããæ²»çå¹æã«é©ããè¬çšéãåŸã
ãããããªå²åãæ§æããããšãå¿ èŠã§ãããæ°
åã®åäœæè¬é圢æ ãã»ãŒåæã«æäžããããã
ãšã¯æããã§ããã
äžè¬ã«ãæ¬çºæã®çµæç©ã¯æ³šå°ã«ããæäžã«å¿
èŠãšãããå Žåã«ã¯éåžžå°ããšã0.025ééïŒ ã®
掻æ§ç©è³ªãå«æããŠããã¹ãã§ãããçµå£æäžã«
ã¯ãã®è£œå€ã¯éåžžå°ããšã0.1ééïŒ ã®æŽ»æ§ç©è³ª
ãå«æããŠããã䜿çšãããçšéã¯ææã®æ²»çå¹
æãæäžçµè·¯ããã³æ²»çã®æç¶æéã«äŸåããã
æ人ã§ã¯ãçšéã¯äžè¬ã«ãäŸãã°ãšãŒããŸã«æäž
ã«ã¯0.02ã2.0mgãéèå æäžã«ã¯0.0002ã2.0
mgïŒäœéKgããããŠçµå£æäžã«ã¯0.001ã1.0mgïŒ
äœéKgã§ãããå¿ èŠãªãã°ãããã®çšéã¯å¿ èŠã«
å¿ããŠå埩ããããã
èŠãšãããå Žåã«ã¯éåžžå°ããšã0.025ééïŒ ã®
掻æ§ç©è³ªãå«æããŠããã¹ãã§ãããçµå£æäžã«
ã¯ãã®è£œå€ã¯éåžžå°ããšã0.1ééïŒ ã®æŽ»æ§ç©è³ª
ãå«æããŠããã䜿çšãããçšéã¯ææã®æ²»çå¹
æãæäžçµè·¯ããã³æ²»çã®æç¶æéã«äŸåããã
æ人ã§ã¯ãçšéã¯äžè¬ã«ãäŸãã°ãšãŒããŸã«æäž
ã«ã¯0.02ã2.0mgãéèå æäžã«ã¯0.0002ã2.0
mgïŒäœéKgããããŠçµå£æäžã«ã¯0.001ã1.0mgïŒ
äœéKgã§ãããå¿ èŠãªãã°ãããã®çšéã¯å¿ èŠã«
å¿ããŠå埩ããããã
ãããŸã§è¿°ã¹ãŠããããšããåŒãæããåå
ç©ã¯è朰çæ£è ããã³èé žéå€çã®æ£è ã®æ²»çã«
éããŠç¹ã«çµå£çµè·¯ã«ããæäžãããå Žåã«ç¹ã«
æçšã§ããã
ç©ã¯è朰çæ£è ããã³èé žéå€çã®æ£è ã®æ²»çã«
éããŠç¹ã«çµå£çµè·¯ã«ããæäžãããå Žåã«ç¹ã«
æçšã§ããã
æ¬çºæã®ååç©ã¯è朰çã®çšåºŠãäœäžãããã
ãããã¯è朰çã®æ¡å€§ãé»æ¢ãããããã«ãæ¬çº
æã®ååç©ã¯èé žåæ³æ°Žæºç¹ã«é£ç©ãããã¯ã¹ã
ã¬ã¹ã«ããåºæ¿ãããéå°ã®èé žåæ³ãæžå°ã
ããåŸã€ãŠèé žã«ããæ¹èµ·ããã朰çã®ç䟯ã®æª
åãæžéãããã
ãããã¯è朰çã®æ¡å€§ãé»æ¢ãããããã«ãæ¬çº
æã®ååç©ã¯èé žåæ³æ°Žæºç¹ã«é£ç©ãããã¯ã¹ã
ã¬ã¹ã«ããåºæ¿ãããéå°ã®èé žåæ³ãæžå°ã
ããåŸã€ãŠèé žã«ããæ¹èµ·ããã朰çã®ç䟯ã®æª
åãæžéãããã
åŒãæããååç©ã¯1.0mg以äžã®çµå£çšéã§
ååããã³äžç¢ãèµ·ããå Žåããããããããã®
ååç©ã«ãšã€ãŠãããçšéæ°Žæºã¯è朰çããã³è
é žéå€çã®æ²»çã«äžè¬ã«å¿ èŠãšãããçšéããã
éå°ã§ãããåŸã€ãŠãæãŸãããã¬å¯äœçšã®çºçŸ
ã¯é©åœãªçšéå²åãéžæããããšã«ããåé¿ãã
ããã
ååããã³äžç¢ãèµ·ããå Žåããããããããã®
ååç©ã«ãšã€ãŠãããçšéæ°Žæºã¯è朰çããã³è
é žéå€çã®æ²»çã«äžè¬ã«å¿ èŠãšãããçšéããã
éå°ã§ãããåŸã€ãŠãæãŸãããã¬å¯äœçšã®çºçŸ
ã¯é©åœãªçšéå²åãéžæããããšã«ããåé¿ãã
ããã
äŸãã°ãåŒã®ååç©ã¯æ¶²äœçµæç©äžã«ãããŠ
0.01mgïŒäœéKgã®çšéãããã¯ã«ãã»ã«äžã«ãã
ãŠ0.02mgïŒäœéKgã®çšéã§ååããã³äžç¢ã®çºçŸ
ããã³æãŸããªãåå®®ã®åçž®ã䌎ãªãããšãªãçµ
å£æäžããããã
0.01mgïŒäœéKgã®çšéãããã¯ã«ãã»ã«äžã«ãã
ãŠ0.02mgïŒäœéKgã®çšéã§ååããã³äžç¢ã®çºçŸ
ããã³æãŸããªãåå®®ã®åçž®ã䌎ãªãããšãªãçµ
å£æäžããããã
åŸã€ãŠãè朰çã®æ人æ£è
ããã³èé
žéå€çã®
æ人æ£è ã®æ²»çã«ã¯äœéïŒKgåœãåŒã®ååç©
0.001ã0.05mgã®çµå£çšéãäžè¬ã«é©åœã§ããã
ç¹ã«ïŒæ¥ïŒãïŒãããã¯ïŒåæäžãããã液äœçµ
æç©ã®åœ¢æ ã®åŒã®ååç©0.001ã0.01mgïŒäœé
Kgã®çµå£çšéãããã¯ã«ãã»ã«å€ã®åœ¢æ ã®åŒã®
ååç©0.001ã0.02mgïŒäœéKgã®çµå£çšéãé©ã
ãŠããã
æ人æ£è ã®æ²»çã«ã¯äœéïŒKgåœãåŒã®ååç©
0.001ã0.05mgã®çµå£çšéãäžè¬ã«é©åœã§ããã
ç¹ã«ïŒæ¥ïŒãïŒãããã¯ïŒåæäžãããã液äœçµ
æç©ã®åœ¢æ ã®åŒã®ååç©0.001ã0.01mgïŒäœé
Kgã®çµå£çšéãããã¯ã«ãã»ã«å€ã®åœ¢æ ã®åŒã®
ååç©0.001ã0.02mgïŒäœéKgã®çµå£çšéãé©ã
ãŠããã
以äžã®å®æœäŸã«ããæ¬çºæã«ããè¬å€çµæç©ã
説æããã
説æããã
å®æœäŸ ïŒ
以äžã®æåã«ãããŒã©ãã³ã«ãã»ã«ïŒãµã€ãºNo.
ïŒïŒãæ £çšã®æ¹æ³ã§è£œé ãããã
ïŒïŒãæ £çšã®æ¹æ³ã§è£œé ãããã
ïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âããšãã
ã·â15âãªããœâ13ïŒ14âãžãããâïŒâãã«
ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ
20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1 0.3mg ä¹³ ç³ 175mg ã§ãã·ã 25mg ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒmg ãšãŒãã·ã«ïŒAerosilïŒïŒåŸ®çŽ°ã«åå²ãããäºé ž
åããçŽ ïŒ ïŒmg å®æœäŸ ïŒ ä»¥äžã®æåã«ãããŒã©ãã³ã«ãã»ã«ïŒãµã€ãºNo.
ïŒïŒãæ £çšã®æ¹æ³ã§è£œé ãããã
ã·â15âãªããœâ13ïŒ14âãžãããâïŒâãã«
ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ
20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1 0.3mg ä¹³ ç³ 175mg ã§ãã·ã 25mg ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒmg ãšãŒãã·ã«ïŒAerosilïŒïŒåŸ®çŽ°ã«åå²ãããäºé ž
åããçŽ ïŒ ïŒmg å®æœäŸ ïŒ ä»¥äžã®æåã«ãããŒã©ãã³ã«ãã»ã«ïŒãµã€ãºNo.
ïŒïŒãæ £çšã®æ¹æ³ã§è£œé ãããã
ïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âããšãã
ã·â15âãªããœâ13ïŒ14âãžãããâïŒâãã«
ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ
20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1 0.3mg ãããã¬ã³ã°ãªã³ãŒã« 0.2ml
ã·â15âãªããœâ13ïŒ14âãžãããâïŒâãã«
ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ
20âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1 0.3mg ãããã¬ã³ã°ãªã³ãŒã« 0.2ml
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒ ïŒåŒäžïŒåã®åŽéã¯ç°ççŽ ååã«ãã©ã³ã¹é 眮
ã«ãŠçµåããŠããïŒ ãæããååç©ã ïŒ ïŒÂ±ïŒâïŒâããããã·ã¡ãã«â16âããšã
ãã·â15âãªããœâ13ïŒ14âãžãããâïŒâãã«
ã«ããã·â11ïŒ15âãžããªãã·â17ïŒ18ïŒ19ïŒ20
âããã©ãã«ããã¹ã¿ã°ã©ã³ãžã³E1ã§ããåèš
第ïŒé ã®ååç©ã ïŒ åŒ ïŒåŒäžïŒåã®åŽéã¯ç°ççŽ ååã«ãã©ã³ã¹é 眮
ã§çµåããŠããïŒ ãæããçžåœããååç©äžã®ççŽ âççŽ äºéçµå
ã觊åªããã³äžæŽ»æ§ææ©æº¶åªã®ååšäžæ°ŽçŽ æ·»å ã
ãããšã«ããéå ããããšãç¹åŸŽãšããåŒ ïŒåŒäžïŒåã®åŽéã¯ç°ççŽ ååã«ãã©ã³ã¹é 眮
ã«ãŠçµåããŠããïŒ ãæããååç©ã®è£œæ³ã ïŒ æ°ŽçŽ æ·»å 觊åªãæšçäžã®ããžãŠã ãããã¯æš
çäžã®ãã©ãžãŠã ã§ããåèšç¬¬ïŒé ã«ããæ¹æ³ã ïŒ ææ©æº¶åªãïŒãïŒåã®ççŽ ååãæããã¢ã«
ã«ããŒã«ã§ããåèšç¬¬ïŒãããã¯ïŒé ã«ããæ¹
æ³ã ïŒ æ°ŽçŽ æ·»å ãåšå²æž©åºŠããã³æ°ŽçŽ å§0.5ã10
KgïŒcm2ã«ãããŠè¡ãããåèšç¬¬ïŒïŒïŒãããã¯ïŒ
é ã«ããæ¹æ³ã ïŒ è£œè¬çšæ äœãããã¯ã³ãŒãã€ã³ã°å€ãšå ±ã«åŒ ïŒåŒäžïŒåã®åŽéã¯ç°ççŽ ååã«ãã©ã³ã¹é 眮
ã«ãŠçµåããŠããïŒ ãæããååç©ãããªãè朰çããã³èé žéå€ç
ã®é²æ¢ã®ããã®è¬å€çµæç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB22319/77A GB1581886A (en) | 1977-05-26 | 1977-05-26 | Prostanol derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53147045A JPS53147045A (en) | 1978-12-21 |
| JPS6151584B2 true JPS6151584B2 (ja) | 1986-11-10 |
Family
ID=10177472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6174578A Granted JPS53147045A (en) | 1977-05-26 | 1978-05-25 | Derivative of cyclopentane and its preparation |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4158062A (ja) |
| JP (1) | JPS53147045A (ja) |
| DE (1) | DE2822751A1 (ja) |
| FR (1) | FR2392005A1 (ja) |
| GB (1) | GB1581886A (ja) |
| HK (1) | HK28784A (ja) |
| IT (1) | IT1094851B (ja) |
| MY (1) | MY8400370A (ja) |
| SG (1) | SG59183G (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8512344D0 (en) * | 1985-05-15 | 1985-06-19 | May & Baker Ltd | Compositions of matter |
| JPH085794B2 (ja) * | 1989-07-27 | 1996-01-24 | æ ªåŒäŒç€Ÿäžé補è¬å¿çšç 究æ | é«è質è¡çåŠçœ®ã»è¡äžè質æåäœäžå€ |
| JPH0769897A (ja) * | 1993-09-01 | 1995-03-14 | Green Cross Corp:The | è¡äžããªã°ãªã»ãªãäœäžäœçšå€ |
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| TWI331920B (en) | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
| JP4889219B2 (ja) * | 2002-12-27 | 2012-03-07 | ã¹ãã£ã³ãã»ã¢ãŒã²ãŒ | è ¹éšäžå¿«æã®åŠçœ®ã®ããã®ããã¹ã¿ã°ã©ã³ãžã³èªå°äœ |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| US20090030072A1 (en) * | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1468830A (en) * | 1974-01-26 | 1977-03-30 | May & Baker Ltd | Cyclopentane derivatives |
-
1977
- 1977-05-26 GB GB22319/77A patent/GB1581886A/en not_active Expired
-
1978
- 1978-05-24 US US05/909,018 patent/US4158062A/en not_active Expired - Lifetime
- 1978-05-24 DE DE19782822751 patent/DE2822751A1/de active Granted
- 1978-05-25 FR FR7815523A patent/FR2392005A1/fr active Granted
- 1978-05-25 JP JP6174578A patent/JPS53147045A/ja active Granted
- 1978-05-26 IT IT23915/78A patent/IT1094851B/it active
-
1983
- 1983-09-15 SG SG591/83A patent/SG59183G/en unknown
-
1984
- 1984-03-29 HK HK287/84A patent/HK28784A/xx unknown
- 1984-12-31 MY MY1984370A patent/MY8400370A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY8400370A (en) | 1984-12-31 |
| US4158062A (en) | 1979-06-12 |
| FR2392005B1 (ja) | 1980-04-04 |
| JPS53147045A (en) | 1978-12-21 |
| SG59183G (en) | 1984-07-27 |
| FR2392005A1 (fr) | 1978-12-22 |
| DE2822751C2 (ja) | 1988-01-28 |
| DE2822751A1 (de) | 1978-12-07 |
| IT1094851B (it) | 1985-08-10 |
| IT7823915A0 (it) | 1978-05-26 |
| GB1581886A (en) | 1980-12-31 |
| HK28784A (en) | 1984-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2902442A1 (de) | 9-deoxy-9a-methylen-isostere von pgi tief 2 , verfahren zu ihrer herstellung und sie enthaltende pharmazeutische und veterinaermedizinische mittel | |
| DE3107100A1 (de) | Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
| JPS6151584B2 (ja) | ||
| EP0142158B1 (en) | Omega-cycloalkyl prostaglandins | |
| JPS5921850B2 (ja) | æ°ããã¿ã¬ã³èªå°äœã®è£œæ³ | |
| EP0350878B1 (en) | Conjugated gamma-oxybutenolide compounds for treating ulcer | |
| DE2627673A1 (de) | Prostaglandinartige 1,15-lactone sowie verfahren zu deren herstellung | |
| GB1574246A (en) | Prostaglandin derivatives and process for preparing the same | |
| EP0051558A1 (de) | Prostacyclinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| US3966745A (en) | Vinvamine series cycloalkyl-alkyl esters | |
| US4034003A (en) | 15-Cycloalkyl-prostaglandins | |
| EP0224208B1 (en) | Tetraenyl prostaglandins | |
| JPS63185974A (ja) | æ°èŠã«ã«ãã¢ã€ã«ãªãã·ã©ããã³é¡ | |
| US4863961A (en) | Tetraenyl prostaglandins | |
| US4062783A (en) | 15-Ethynyl substituted prostanoic acids | |
| US4754059A (en) | Omega cycloalkyl prostaglandins | |
| EP0418655B1 (en) | Conjugated gamma-hydroxybutenolide compounds and antiulcer agents containing the same as an effective ingredient | |
| DE3035454A1 (de) | 7-oxoprostacyclinderivate und verfahren zu ihrer herstellung | |
| DE3335389A1 (de) | 15-cycloaliphatische derivate von 13,14-didehydrocarboprostacyclinen, verfahren zu deren herstellung sowie pharmazeutische oder veterinaere mittel, die diese enthalten | |
| Matsumuraa et al. | Synthesis and biological properties of novel fluoroprostaglandin derivatives: Highly selective and potent agonists for prostaglandin receptors | |
| JPH024590B2 (ja) | ||
| US4713477A (en) | Omega cycloalkyl prostaglandins | |
| HU182726B (en) | Process for producing the 9-desoxy-9a-methylene-isosteres of pgi2/prostacyclin/ | |
| EP0163672A1 (de) | 20-alkyl-7-oxoprostacyclinderivate und verfahren zu ihrer herstellung. | |
| DE3507944A1 (de) | Furyl- und imidazolylderivate von carboprostacyclinen, verfahren zu deren herstellung und arzneimittel, welche diese enthalten |